home / stock / bold / bold news

BOLD News and Press, Audentes Therapeutics Inc. From 05/07/19

Stock Information
Company Name: Audentes Therapeutics Inc.
Stock Symbol: BOLD
Market: NASDAQ
Website: boundlessbio.com
Menu
BOLD BOLD Quote BOLD Short BOLD News BOLD Articles BOLD Message Board
Get BOLD Alerts

News, Short Squeeze, Breakout and More Instantly...
BOLD - Audentes Therapeutics' (BOLD) CEO Matt Patterson on Q1 2019 Results - Earnings Call Transcript

Audentes Therapeutics , Inc. (BOLD) Q12 2019 Results Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Andrew Chang – Head-Investor Relations Matt Patterson – Chairman and Chief Executive Officer Conference Call Participants Anupam Rama ȁ...
BOLD - Audentes Therapeutics misses by $0.24

Audentes Therapeutics (NASDAQ: BOLD ): Q1 GAAP EPS of -$1.13 misses by $0.24 . Cash and equivalents of $378.8M. Press Release More news on: Audentes Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

BOLD - Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

SAN FRANCISCO , May 7, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for the fi...

BOLD - Audentes Therapeutics (BOLD) Presents At Annual Meeting of the American Society of Gene and Cell Therapy - Slideshow

The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...

BOLD - Audentes gene therapy for rare neuromuscular disorder shows positive action in study

Updated data from a Phase 1/2 clinical trial, ASPIRO , evaluating Audentes Therapeutics' ( BOLD -0.6% ) gene therapy candidate AT132 in patients with X-linked myotubular myopathy (XLMTM) showed a treatment effect. The results were presented at the American Society of Gene and Cell Ther...

BOLD - Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy

SAN FRANCISCO , May 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced new positive data from ASPIRO, ...

BOLD - Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019

SAN FRANCISCO , April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to r...
BOLD - Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility

SAN FRANCISCO , April 23, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced the launch of a new sta...

BOLD - Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy

SAN FRANCISCO , April 15, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced multiple planned presen...

BOLD - Audentes Therapeutics (BOLD) Conference Call on Expansion of AAV Technology Platform and Pipeline - Slideshow

The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...

Previous 10 Next 10